CHMA News and Press, Chiasma Inc. From 04/15/19

Gainers: CHMA   +4.3% . JMIA   +2.5% . PCB   +2.1% . FTEK   +1.9% . More news on: Chiasma, Inc., Jumia Technologies AG, Pacific City Financial Corporation, Stocks on the move, Read more ...

Chiasma (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, recently announced the closing of its underwritten public offering of 7,263,158 shares of its common stock at a price to the public of $4.75 eac...

WALTHAM, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has closed its previously announced underwritten public offe...

Chiasma (NASDAQ: CHMA ) announced the pricing of an underwritten public offering of ~6.32M shares of its common stock at a price of $4.75/share & expected to close on or about April 2, 2019. More news on: Chiasma, Inc., Read more ...

WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of an underwritten public offering of 6,315,790 shares o...

ENDRA Life Sciences (NASDAQ: NDRA ) -28%  on reporting initial findings on first human TAEUS feasibility study of liver fat. More news on: ENDRA Life Sciences Inc., Chiasma, Inc., SMART Global Holdings, Inc., Stocks on the move, Read more ...

WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has commenced an underwritten public offering of its common ...

WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced three poster presentations at ENDO 2019: The Endocrine Societyȁ...

Chiasma (NASDAQ: CHMA ): Q4 GAAP EPS of -$0.32. More news on: Chiasma, Earnings news and commentary, Healthcare stocks news, , Read more ...

On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA ®, expected in Q3 2019 Assuming positive OPTIMAL data , NDA submission expected by year-end 2019 WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Chia...